Compare Union Pacific Corporation (UNP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Union Pacific Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Union Pacific Corporation trades at $278.62 (market cap $165.27B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Union Pacific Corporation is far larger — about 16.3× State Street SPDR S&P Biotech ETF's market cap, and Union Pacific Corporation pays a 2.04% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Union Pacific Corporation for 105 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| UNP | XBI | |
|---|---|---|
Market Cap | $165.27B | $10.11B |
Volume | 1,474,117 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $310.62 | $169.55 |
52-Week Low | $216.37 | $104.99 |
Typical Hold Time | 105 Days | 38 Days |
Enterprise Value | $194.33B | — |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Union Pacific (UNP) trades at $277.51, up 1.03% with a bullish technical signal and strong fundamental performance. The stock shows robust profitability with 28.85% net margins and 39.7% ROE, supported by consecutive earnings beats in Q1 and Q2 2026. Recent developments include the deployment of battery-electric locomotives and progress on the Norfolk Southern combination, while analyst consensus remains strongly positive with a $332.10 price target.
UNP presents a compelling investment case with strong operational execution and pricing power, though merger uncertainty and fuel cost pressures pose near-term risks. The stock's current valuation at 22.53 P/E offers reasonable upside to analyst targets, supported by consistent dividend payments and infrastructure advantages in the irreplaceable freight rail network.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
